1.No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study
Jin Ju LEE ; Bo Ram KWON ; Min Young LEE ; Ji Yeon BYUN ; Joo Young ROH ; Hae Young CHOI ; You Won CHOI
The Ewha Medical Journal 2025;48(1):e78-
2.No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study
Jin Ju LEE ; Bo Ram KWON ; Min Young LEE ; Ji Yeon BYUN ; Joo Young ROH ; Hae Young CHOI ; You Won CHOI
The Ewha Medical Journal 2025;48(1):e78-
3.No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study
Jin Ju LEE ; Bo Ram KWON ; Min Young LEE ; Ji Yeon BYUN ; Joo Young ROH ; Hae Young CHOI ; You Won CHOI
The Ewha Medical Journal 2025;48(1):e78-
4.No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study
Jin Ju LEE ; Bo Ram KWON ; Min Young LEE ; Ji Yeon BYUN ; Joo Young ROH ; Hae Young CHOI ; You Won CHOI
The Ewha Medical Journal 2025;48(1):e78-
5.No difference in inflammatory mediator expression between mast cell-rich and mast cell-poor rosacea lesions in Korean patients: a comparative study
Jin Ju LEE ; Bo Ram KWON ; Min Young LEE ; Ji Yeon BYUN ; Joo Young ROH ; Hae Young CHOI ; You Won CHOI
The Ewha Medical Journal 2025;48(1):e78-
6.Real-World Clinical Practice on Skin Rejuvenation Among Korean BoardCertified Dermatologists: SurveyBased Results
Sejin OH ; Yeong Ho KIM ; Bo Ri KIM ; Hyun-Min SEO ; Soon-Hyo KWON ; Hoon CHOI ; Haewoong LEE ; Jung-Im NA ; Chun Pill CHOI ; Joo Yeon KO ; Hwa Jung RYU ; Suk Bae SEO ; Jong Hee LEE ; Hei Sung KIM ; Chang-Hun HUH
Annals of Dermatology 2025;37(3):123-130
Background:
Skin rejuvenation has become an increasingly popular noninvasive approach to address age-related changes such as sagging, wrinkles, and skin laxity. Energy-based devices (EBDs) and injectables are widely used, but their application requires careful customization based on individual patient characteristics to optimize outcomes and minimize potential adverse effects.
Objective:
This study aimed to explore clinical practice patterns among board-certified dermatologists in South Korea, focusing on their strategies for tailoring skin rejuvenation treatments to individual patients, including the integration of EBDs, injectables, and senotherapeutics.
Methods:
A structured survey comprising 10 questions was administered to 13 experienced dermatologists specializing in skin rejuvenation. The survey covered treatment strategies for patients with varying facial fat volumes, pain management approaches, and the use of EBDs, injectables and senotherapeutics.
Results:
High-intensity focused ultrasound (HIFU) and radiofrequency (RF) were the most employed EBDs, often combined with injectables for enhanced outcomes. For patients with higher facial fat, HIFU and deoxycholic acid injections were preferred for contouring and tightening. For those with lower facial fat, biostimulatory agents such as poly-D, L-lactic acid and microneedle RF were favored to restore volume and elasticity. Pain management strategies included topical anesthetics and stepwise protocols. Although less commonly used, senotherapeutics were occasionally prescribed for specific conditions, such as melasma and extensive photoaging.
Conclusion
Dermatologists in South Korea employ a variety of patient-specific strategies for skin rejuvenation, combining various EBDs, injectables, and senotherapeutics. These findings highlight the importance of personalized treatment protocols and the need for further research to optimize treatment efficacy and safety.
7.Ethanol Extracts of Cornus alba Improve Benign Prostatic Hyperplasia by Inhibiting Prostate Cell Proliferation through Modulating 5 Alpha-Reductase/ Androgen Receptor Axis-Mediated Signaling
Byungdoo HWANG ; Jongyeob KIM ; Solbi PARK ; Hyun Joo CHUNG ; Hoon KIM ; Yung Hyun CHOI ; Wun-Jae KIM ; Soon Chul MYUNG ; Tae-Bin JEONG ; Kyung-Mi KIM ; Jae-Chul JUNG ; Min-Won LEE ; Jin Wook KIM ; Sung-Kwon MOON
The World Journal of Men's Health 2024;42(4):830-841
Purpose:
The aim of this study was to investigate the efficacy of ethanol extracts of Cornus alba (ECA) against benign prostatic hyperplasia (BPH) in vitro and in vivo.
Materials and Methods:
The prostate stromal cells (WPMY-1) and epithelial cells (RWPE-1) were used to examine the action mechanism of ECA in BPH in vitro. ECA efficacy was evaluated in vivo using a testosterone propionate (TP)-induced BPH rat model.
Results:
Treatment with ECA inhibited the proliferation of prostate cells by inducing G1-phase cell cycle arrest through the regulation of positive and negative proteins. Treatment of prostate cells with ECA resulted in alterations in the mitogen-activated protein kinases and protein kinase B signaling pathways. The transcriptional binding activity of the NF-κB motif was suppressed in both ECA-treated prostate cells. In addition, treatment with ECA altered the level of BPH-associated axis markers (5α-reductase, fibroblast growth factor-2, androgen receptor, epidermal growth factor, Bcl-2, and Bax) in both cell lines. Finally, the administration of ECA attenuated the enlargement of prostatic tissues in the TP-induced BPH rat model, accompanied by histology, immunoblot, and serum dihydrotestosterone levels.
Conclusions
These results demonstrated that ECA exerted beneficial effects on BPH both in vitro and in vivo and might provide valuable information in the development of preventive or therapeutic agents for improving BPH.
8.Catalpa bignonioides extract improves exercise performance through regulation of growth and metabolism in skeletal muscles
Hoibin Jeong ; Dong-joo Lee ; Sung-Pil Kwon ; SeonJu Park ; Song-Rae Kim ; Seung Hyun Kim ; Jae-Il Park ; Deug-chan Lee ; Kyung-Min Choi ; WonWoo Lee ; Ji-Won Park ; Bohyun Yun ; Su-Hyeon Cho ; Kil-Nam Kim
Asian Pacific Journal of Tropical Biomedicine 2024;14(2):47-54
Objective: To evaluate the effects of Catalpa bignonioides fruit extract on the promotion of muscle growth and muscular capacity in vitro and in vivo. Methods: Cell viability was measured using the 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide assay. Cell proliferation was assessed using a 5-bromo-2’-deoxyuridine (BrdU) assay kit. Western blot analysis was performed to determine the protein expressions of related factors. The effects of Catalpa bignonioides extract were investigated in mice using the treadmill exhaustion test and whole-limb grip strength assay. Chemical composition analysis was performed using high-performance liquid chromatography (HPLC). Results: Catalpa bignonioides extract increased the proliferation of C2C12 mouse myoblasts by activating the Akt/mTOR signaling pathway. It also induced metabolic changes, increasing the number of mitochondria and glucose metabolism by phosphorylating adenosine monophosphate-activated protein kinase. In an in vivo study, the extract-treated mice showed improved motor abilities, such as muscular endurance and grip strength. Additionally, HPLC analysis showed that vanillic acid may be the main component of the Catalpa bignonioides extract that enhanced muscle strength. Conclusions: Catalpa bignonioides improves exercise performance through regulation of growth and metabolism in skeletal muscles, suggesting its potential as an effective natural agent for improving muscular strength.
9.Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea
Byung-Joon KIM ; Jun-Seop SHIN ; Byoung-Hoon MIN ; Jong-Min KIM ; Chung-Gyu PARK ; Hee-Jung KANG ; Eung Soo HWANG ; Won-Woo LEE ; Jung-Sik KIM ; Hyun Je KIM ; Iov KWON ; Jae Sung KIM ; Geun Soo KIM ; Joonho MOON ; Du Yeon SHIN ; Bumrae CHO ; Heung-Mo YANG ; Sung Joo KIM ; Kwang-Won KIM
Diabetes & Metabolism Journal 2024;48(6):1160-1168
Background:
Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods:
A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion
A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
10.COVID-19 Vaccination Recommendations for 2024–2025 in Korea
Wan Beom PARK ; Young Hoon HWANG ; Ki Tae KWON ; Ji Yun NOH ; Sun Hee PARK ; Joon Young SONG ; Eun Ju CHOO ; Min Joo CHOI ; Jun Yong CHOI ; Jung Yeon HEO ; Won Suk CHOI ;
Infection and Chemotherapy 2024;56(4):453-460
The Korean Society of Infectious Diseases has been regularly publishing guidelines for adult immunization since 2007. Following the release of coronavirus disease 2019 (COVID-19) vaccination recommendations in 2023, significant changes have occurred due to the emergence of new variant strains and the waning immunity from previous vaccinations. This article provides a comprehensive update as of November 2024, incorporating the latest evidence and guidelines. Focusing on the 2024–2025 season, this article reviews vaccines currently authorized in Korea and assesses their effectiveness against the predominant JN.1 lineage variants. The updated recommendations prioritize high-risk groups, including adults aged 65 and older, individuals with underlying medical conditions, residents of facilities vulnerable to infection, pregnant women, and healthcare workers, for vaccination with updated vaccines targeting the JN.1 strain. Additionally, COVID-19 vaccination is available for all individuals aged 6 months and older. For most adults, a single-dose strategy is emphasized, while tailored schedules may be recommended for immunocompromised individuals. This update aims to optimize vaccination strategies in Korea to ensure comprehensive protection for high-risk populations.

Result Analysis
Print
Save
E-mail